Federated Hermes Inc. Boosts Stake in DaVita Inc. (NYSE:DVA)

Federated Hermes Inc. lifted its holdings in DaVita Inc. (NYSE:DVA) by 6,158.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,979 shares of the company’s stock after buying an additional 76,733 shares during the period. Federated Hermes Inc. owned approximately 0.09% of DaVita worth $8,169,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Daiwa Securities Group Inc. raised its stake in DaVita by 3.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 4,802 shares of the company’s stock worth $503,000 after purchasing an additional 171 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in DaVita by 28.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 95,657 shares of the company’s stock valued at $10,021,000 after buying an additional 21,205 shares in the last quarter. Everence Capital Management Inc. acquired a new stake in DaVita in the fourth quarter valued at $393,000. LifePlan Financial LLC acquired a new stake in DaVita in the fourth quarter valued at $224,000. Finally, Sippican Capital Advisors raised its stake in DaVita by 19.0% in the fourth quarter. Sippican Capital Advisors now owns 15,618 shares of the company’s stock valued at $1,636,000 after buying an additional 2,496 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now owns 488,697 shares of the company’s stock, valued at approximately $61,629,578.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Michael David Staffieri sold 29,488 shares of DaVita stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the completion of the transaction, the chief operating officer now directly owns 37,687 shares in the company, valued at approximately $4,515,279.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock valued at $16,551,071 over the last quarter. 1.40% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DVA. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 16th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Truist Financial raised their price target on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research note on Tuesday, February 20th. Barclays assumed coverage on DaVita in a report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective on the stock. Finally, UBS Group raised their price objective on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Stock Performance

Shares of DVA stock opened at $132.75 on Thursday. The stock’s 50-day moving average is $131.63 and its two-hundred day moving average is $110.00. The firm has a market cap of $11.64 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 1.19 and a beta of 1.04. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $141.54. The company has a debt-to-equity ratio of 6.65, a quick ratio of 1.13 and a current ratio of 1.19.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.01 billion. During the same quarter last year, the company posted $1.11 earnings per share. The business’s revenue was up 7.8% on a year-over-year basis. Analysts predict that DaVita Inc. will post 9.23 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.